Vistra has been chosen by AMR Action Fund, a public-private partnership supporting the development of new antibiotics, to provide fund administration and a multi-country, multi-service solution to help bring new antibiotics to market.
The AMR Action Fund, a global venture capital fund, is an initiative of the International Federation of Pharmaceutical Manufacturers & Associations, in collaboration with the World Health Organization, the European Investment Bank, and the Wellcome Trust. It aims to bring two to four new antibiotics to patients by 2030.
The fund aims to accelerate the development of antibiotics by investing more than $1bn in smaller biotech companies and providing industry expertise to support the clinical development of novel antibiotics.
Vistra is supporting the fund across its entire structure, management company, special-purpose vehicles and portfolio company investments, enabling it to focus on sourcing investments across its US and Luxembourg funds.
Henry Skinner, CEO at AMR Action Fund, commented: “Antimicrobial resistance [AMR] is a global issue that could have public health and economic consequences greater than Covid-19. We need to act swiftly and purposefully to address the threat, and working with Vistra has enabled us to do that.”